DR. JAMES WILLIAM LARRICK, MD PHD
Osteopathic Medicine at Bordeaux Dr, Sunnyvale, CA
License number
California G45346
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1230 Bordeaux Dr, Sunnyvale, CA 94089
Phone
(415) 263-6311
Professional information
James W Larrick, Sunnyvale CA
Specialties:
Infectious Disease Medicine, Medical Oncology, Oncology
Address:
1230 Bordeaux Dr, Sunnyvale 94089
(408) 747-5201 (Phone)
(408) 747-5201 (Phone)
Languages:
English
Education:
Medical School
Duke University
Graduated: 1980
Duke University
Graduated: 1980
James William Larrick, Sunnyvale CA
Specialties:
Allergy & Immunology
Work:
Galaxy Biotech. LLC
1230 Bordeaux Dr, Sunnyvale, CA 94089
1230 Bordeaux Dr, Sunnyvale, CA 94089
Education:
Duke University(1980)
James William Larrick, Sunnyvale CA
Specialties:
Internist
Address:
1230 Bordeaux Dr, Sunnyvale, CA 94089
Chloramphenicol Acetyl Transferase (Cat)-Defective Somatostatin Fusion Protein And Uses Thereof
US Patent:
8367073, Feb 5, 2013
Filed:
Mar 23, 2011
Appl. No.:
13/069592
Inventors:
Andrew R. Mendelsohn - Sunnyvale CA, US
Keith N. Haffer - Garretson SD, US
James Larrick - Sunnyvale CA, US
Keith N. Haffer - Garretson SD, US
James Larrick - Sunnyvale CA, US
Assignee:
Braasch Biotech, LLC - Garretson SD
International Classification:
A61K 39/00
US Classification:
4241981, 4241851, 530311
Abstract:
Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.
Methods For Enhanced Somatostatin Immunogenicity In The Treatment Of Obesity
US Patent:
2013014, Jun 13, 2013
Filed:
Feb 19, 2013
Appl. No.:
13/770118
Inventors:
BRAASCH BIOTECH LLC - Garretson SD, US
James Larrick - Sunnyvale CA, US
Andrew R. Mendelsohn - Sunnyvale CA, US
James Larrick - Sunnyvale CA, US
Andrew R. Mendelsohn - Sunnyvale CA, US
Assignee:
BRAASCH BIOTECH LLC - Garretson SD
International Classification:
A61K 39/00, A61K 39/39
US Classification:
42419511, 4241841, 4242781
Abstract:
Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1.
Methods For Enhanced Somatostatin Immunogenicity In The Treatment Of Obesity
US Patent:
8425914, Apr 23, 2013
Filed:
Jun 24, 2009
Appl. No.:
12/523952
Inventors:
Keith N. Haffer - Garretson SD, US
James Larrick - Sunnyvale CA, US
Andrew R. Mendelsohn - Sunnyvale CA, US
James Larrick - Sunnyvale CA, US
Andrew R. Mendelsohn - Sunnyvale CA, US
Assignee:
Braasch Biotech LLC - Garretson SD
International Classification:
C07K 14/655, C12N 9/1033, A61K 2039/55566, C07K 2319/00, C07K 2319/31
US Classification:
4241851, 4241981, 4242781, 514909
Abstract:
Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1.
Compositions And Methods Relating To Modulation Of Immune System Components
US Patent:
2010001, Jan 21, 2010
Filed:
Mar 22, 2007
Appl. No.:
12/225459
Inventors:
Tracy Hussell - Kent, GB
James W. Larrick - Sunnyvale CA, US
George L. Foltin - New York NY, US
James W. Larrick - Sunnyvale CA, US
George L. Foltin - New York NY, US
International Classification:
A61K 39/395, A61K 38/16
US Classification:
4241341, 514 12
Abstract:
A composition comprising a molecular blockade agent to a costimulatory molecule which costimulatory molecule satisfies the following criteria: a. absent in naÊve or resting T-lymphocytes; b. inducible; c. expressed; and d. prominent at the height of an immunopathological response, such as a disease/condition response. Preferably, the costimulatory molecule is OX40 and the molecular blockade agent is an antibody or antibody fragment having antibody activity to OX40. Further, the system may involve modulation of the molecular signal pathway of the aforesaid costimulatory molecule.
Chloramphenicol Acetyl Transferase (Cat)-Defective Somatostatin Fusion Protein And Uses Thereof
US Patent:
7943143, May 17, 2011
Filed:
Feb 10, 2010
Appl. No.:
12/703631
Inventors:
Andrew R. Mendelsohn - Sunnyvale CA, US
Keith N. Haffer - Garretson SD, US
James Larrick - Sunnyvale CA, US
Keith N. Haffer - Garretson SD, US
James Larrick - Sunnyvale CA, US
Assignee:
Braasch Biotech LLC - Garretson SD
International Classification:
A61K 39/00
US Classification:
4241981, 4241851, 530311
Abstract:
Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.